Alfasigma's $800 million buyout of Intercept Pharma two years ago is starting to look like a poor bet, as its only approved product, Ocaliva, is pulled off the market in the US and all trials of the ...
Intercept Pharmaceuticals has accused the FDA of moving the goalposts during its review of a potential blockbuster drug for the fatty liver disease known as NASH following a rejection. Intercept’s CEO ...
Westgold Resources Limited (ASX: WGX) (TSX: WGX) (Westgold or the Company) is pleased to announce it has entered into a ...
Origen Resources Inc. is pleased to announce results from the recently completed LiDAR and rock sampling programs on its 100%-owned, road accessible Broken Handle and Bonanza projects located north of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback